Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a protein receptor on T immune cells that prevents the cells from killing other cells, such as cancer cells. Blocking CTLA-4 with a specific antibody is an effective treatment for some cancers, but it can damage the heart. New research published in The FASEB Journal reveals the mechanisms involved in this side effect—a finding that could be used to help prevent it.
Experiments conducted in mice showed that blocking CTLA-4 activates certain T cells called Th17 cells, which increase inflammation. Inhibiting this activation reversed anti-CTLA-4–mediated heart damage.
“Targeting this axis could potentially offer a preventive or therapeutic strategy for managing cardiotoxicity in patients undergoing anti-CTLA-4-based immune checkpoint inhibitor therapy,” the authors wrote.
More information:
Blocking CTLA-4 promotes pressure overload-induced heart failure via activating Th17 cells, The FASEB Journal (2024). DOI: 10.1096/fj.202400384R
Citation:
How an effective cancer therapy may damage the heart (2024, August 7)
retrieved 7 August 2024
from https://medicalxpress.com/news/2024-08-effective-cancer-therapy-heart.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
